Merck's Oral Peptide PCSK9 Inhibitor Enlicitide Decanoate Shows Superior LDL-C Reductions
Merck's investigational oral macrocyclic peptide PCSK9 inhibitor demonstrated significantly greater LDL-C reductions at 8 weeks vs guideline-recommended oral non-statin therapies, delivering injectable-level cholesterol lowering in pill form.